Fresenius Medical Care (FMS) Stock: Buy, Sell, or Hold?
FMS - Fresenius Medical Care AG
$22.62
0.12 (0.53%)
â˛
5d:
+4.92%
30d:
+1.57%
90d:
-11.98%
WAIT
LOW Confidence
Analysis Updated: Oct 28, 2026 12:00 AM ET
Earnings: Nov 03, 2026
4d
Get Alerted When FMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: FMS is fairly priced but lacks strong directional signals. At 6.0% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: FMS is fairly priced but lacks strong directional signals. At 6.0% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.16
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$23.08
2.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FMS is currently trading at $22.62, which is considered slightly high relative to its 30-day fair value range of $21.45 to $22.68. From a valuation perspective, the stock is trading at a premium (Forward PE: 8.5) compared to its historical average (7.2). At these levels, the market is pricing in 6.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FMS is in a downtrend. The price is approaching resistance at $22.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: FMS scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FMS is in a downtrend. The price is approaching resistance at $22.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: FMS scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$21.45 -
$22.68
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
37.1%
All Signals
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($23.68)
- NEUTRAL: Trading at premium valuation - market expects 6.0% growth which is achievable
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$21.45 -
$22.68
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$20.91
Resistance Level
$22.99
Current Trend
Downtrend
Technical data as of
Oct 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.53
Wall Street Target
$23.68
(+4.7%)
Revenue Growth (YoY)
1.4%
Earnings Growth (YoY)
5.5%
Profit Margin
4.8%
Valuation Premium vs History
+6.0% premium
PE vs Historical
8.5 vs 7.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.0%
(market-implied from PE analysis)
1-Year Target
$23.98
(+6%)
2-Year Target
$25.42
(+12%)
3-Year Target
$26.94
(+19%)
3-Yr Target (if PE normalizes)
(PE: 9â7)
PE COMPRESSION
$22.73
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 27.9%)
$110.15
(+387%)
Base:
(SPY PE: 8.5, Growth: 27.9%)
$47.33
(+109%)
Bear:
(PE: 7.2, Growth: 27.9%)
$39.93
(+77%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 11.60 | Current EPS (TTM): $1.94
Bull Case
$33.82
(+50%)
Analyst growth 36.6%, PE expands to 12.8
Base Case
$30.74
(+36%)
Market implied 36.6%, PE stable at 11.6
Bear Case
$15.30
(-32%)
Severe decline -20.0%, PE contracts to 9.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 29, 2026 5:15 AM ET
Data refreshes hourly during market hours. Next update: 6:15 AM
Data refreshes hourly during market hours. Next update: 6:15 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare CorporaâĻ |
STRONG BUY
23 analysts |
$286 | 54 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
26 analysts |
$462 | 47 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
13 analysts |
$148 | 56 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
16 analysts |
$24 | 47 HOLD |
|
GRDN
Guardian Pharmacy ServicâĻ |
STRONG BUY
7 analysts |
$50 | 61 BUY |
